Re: PDDI Min Info Model Task Force - Please review penultimate Community Group Note by 5/17/18

I read the rest of the document, and overall I am very impressed. It's very
good. There are some minor comments:

- PDF should have page numbers. I found it difficult to navigate it when
printed.
- In the appendix, it's possible to specify an ingredient level entity in
RxNorm (or Clinical Dose Form Group) to avoid having to specify every
single drug.
- In the straw man XMLs, besides my comment regarding the MPIO tags, if you
have references section, they should be all together in a single tag, b/c
they are usually shared. We shouldn't have references for each section.
- There is a stray ">>>> master" near the end of the document.

--Sam

On Mon, Apr 30, 2018 at 10:51 AM, Sam Habiel <sam.habiel@gmail.com> wrote:

> Rich,
>
> I didn't finish the document yet, but there were two issues that I
> previously raised that were not addressed:
>
> I do not think Seriousness and Severity are semantically different to
> readers. I would rather you use "Morbidity" and "Reaction Intensity" for
> these terms. At least I can sorta tell these apart.
>
> I would rather the sample XML use tags that do not include colons and are
> semantically meaningful. <interaction></interaction> rather than
> <MPIO:1111000>, which is meaningless to me.
>
>
> --Sam
>
>
> On Thu, Apr 26, 2018 at 11:15 AM, Richard Boyce <rdb20@pitt.edu> wrote:
>
>> Dear Task Force Colleagues,
>>
>> I am pleased to announce that we have completed major revision on the
>> draft community group note  on the topic of a potential drug-drug
>> interaction (PDDI) minimum information model. The content of the note is
>> not very different from prior versions but the organization and format is
>> considerably changed with the goal of making it a much more usable report
>> for a technical audience.
>>
>> I have checked with the other editors on this note and have received very
>> positive feedback. I am asking all contributors for any final feedback
>> before we officially publish as W3C Community Group Note.
>>
>> You can view the note here:
>>
>> - Temporary web location (what the note will ultimately look like):
>> https://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/hcls-drug-
>> drug-interaction/index.html
>>
>> - Word and PDF versions in case you want to make edits/comments (please
>> note that the final version of this will be rendered as shown on the web
>> version)
>>
>> Please reply directly to me or on the Community Group mailing list (
>> public-hclscg@w3.org) with any comments, edits, or concerns within three
>> weeks (by May 17th). Please ensure that your name and affiliation is
>> written correctly. Also, an funding acknowledgement that needs mentioned.
>>
>> thanks a bunch!
>>
>> -Rich
>>
>> --
>> Richard D Boyce, PhD
>> Associate Professor of Biomedical Informatics and Clinical and
>> Translational Science in the Clinical and Translational
>> Science Institute
>> Director of the Informatics Core for the Center of Excellence for Natural
>> Product- Drug Interaction Research (NaPDI)
>> Faculty, Center for Pharmaceutical Policy and Prescribing
>> Faculty, Geriatric Pharmaceutical Outcomes and Gero-Informatics Research
>> and Training Program
>> University of Pittsburgh
>> rdb20@pitt.edu
>> Office: 412-648-9219
>> Twitter: @bhaapgh
>>
>>
>